Anti-MCP-1 antibodies, compositions, methods and uses
    13.
    发明申请
    Anti-MCP-1 antibodies, compositions, methods and uses 有权
    抗MCP-1抗体,组合物,方法和用途

    公开(公告)号:US20060039913A1

    公开(公告)日:2006-02-23

    申请号:US11170453

    申请日:2005-06-29

    申请人: Anuk Das Jill Carton

    发明人: Anuk Das Jill Carton

    IPC分类号: A61K39/395 C07K16/40

    摘要: The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

    摘要翻译: 本发明涉及至少一种新的抗MCP-1抗体,包括编码至少一种抗MCP-1抗体,MCP-1,载体,宿主细胞,转基因动物或植物的分离的核酸,以及制备方法 包括治疗组合物,方法和装置。

    Anti-MCP-1 antibodies, compositions, methods and uses
    14.
    发明授权
    Anti-MCP-1 antibodies, compositions, methods and uses 有权
    抗MCP-1抗体,组合物,方法和用途

    公开(公告)号:US07371825B2

    公开(公告)日:2008-05-13

    申请号:US11170453

    申请日:2005-06-29

    IPC分类号: C07K16/00 C12P21/08 C07K1/00

    摘要: The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

    摘要翻译: 本发明涉及至少一种新的抗MCP-1抗体,包括编码至少一种抗MCP-1抗体,MCP-1,载体,宿主细胞,转基因动物或植物的分离的核酸,以及制备方法 包括治疗组合物,方法和装置。

    Method of pulmonary administration of an agent
    16.
    发明申请
    Method of pulmonary administration of an agent 审中-公开
    药物的肺部给药方法

    公开(公告)号:US20050025822A1

    公开(公告)日:2005-02-03

    申请号:US10856559

    申请日:2004-05-27

    IPC分类号: A61K9/00 A61K9/127 C12N15/88

    摘要: A method for administering a therapeutic or diagnostic agent to a subject is described. The method includes providing a suspension of liposomes comprised of one or more of vesicle-forming lipids selected from (i) a vesicle-forming lipid derivatized with a hydrophilic polymer and (ii) a neutral lipopolymer, said liposomes being associated with said therapeutic or diagnostic agent, forming an aerosol of said liposome suspension; and administering the aerosol to the subject by inhalation. The liposome formulation delivers intact liposomal particles to the respiratory tract of said subject to form a depot of therapeutic agent therein with no observable provocation of an immune response, as measured by neutrophil or macrophage cell count in the lung after administration.

    摘要翻译: 描述了向受试者施用治疗剂或诊断剂的方法。 该方法包括提供脂质体的悬浮液,其由一种或多种形成囊泡的脂质组成,所述脂质体选自(i)用亲水性聚合物衍生的囊泡形成脂质和(ii)中性脂质聚合物,所述脂质体与所述治疗或诊断相关联 形成所述脂质体悬浮液的气溶胶; 并通过吸入将烟雾剂施用于受试者。 脂质体制剂将完整的脂质体颗粒递送到所述受试者的呼吸道,以在其中形成治疗剂的贮库,其中不存在可观察到的免疫应答挑衅,如通过给药后肺中的嗜中性粒细胞或巨噬细胞细胞计数所测量的。